地舒单抗如何使用

[Drug name] Generic name: Desosumab injection; Trade name: Angavir

【Ingredients】Angavir (desosomeumab) is a human IgG2 monoclonal antibody that binds to human RANKL. The molecular weight of denosumab is approximately 147 kDa. Each single-dose vial of Angavir contains 120 mg of denosumab, sorbitol (4.6%), polysorbate 20 (0.01%), water for injection (USP), acetate (18 mM), and sodium hydroxide, pH 5.2.

[Properties] It is a clear, colorless to light yellow solution.

[Indications] It is used to treat giant cell tumors of bone that are unresectable or whose surgical resection may cause severe functional disability, including adults and adolescent patients with skeletal maturity (defined as at least 1 mature long bone and body weight ≥45 kg).

[Specification] 120 mg (1.7 mL)/bottle

[Dosage and Dosage] Desosumab can only be administered by the subcutaneous route. The recommended dose is 120 mg once every 4 weeks, with an additional dose of 120 mg on the 8th and 15th days of the first month of treatment. Administer subcutaneously in the upper arms, upper thighs, or abdomen. On this basis, calcium and vitamin D also need to be given simultaneously to treat or prevent hypocalcemia and cannot be combined with bisphosphonates.

Patients with giant cell tumor of bone should undergo comprehensive evaluation at regular intervals during treatment with denosumab to determine their condition and maintain continued benefit. The impact of interrupting or discontinuing therapy has not been evaluated in patients with giant cell tumor of bone whose disease state is controllable with denosumab.

[Side Effects and Adverse Reactions] Headache, back pain, headache, fatigue, nausea and limb pain may occur when using denosumab for the treatment of giant cell tumor of bone. The most common serious adverse reactions included osteonecrosis of the jaw (ONJ), osteomyelitis (incidence 0.7%), and dyspnea (0.4%).

[Treatment Contraindications] Preexisting hypocalcemia must be corrected before treatment with denosumab (see [Precautions]). Angavir is contraindicated in patients known to have clinically significant hypersensitivity reactions to denosumab or any component of Angavir (see Precautions, Adverse Reactions).

The above information is collected and compiled. Different patients have different tolerances and specific disease conditions. Therefore, it is for reference only. It is recommended that you consult a doctor or professional.